Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 120

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 120
---
 into of this Agreement nor the acquisition of Common Shares pursuant to the Arrangement will trigger any change of control, severance, retention, termination or transaction bonus or similar provisions in or result in any 
 obligation on the part of the Company or its Subsidiary to make any such payment under any Contract to which the Company or its Subsidiary is a party or by which they are bound.                                                                 |

| (b) | The Purchaser shall not have any additional payment or other obligation in respect of change of control,                                                                           
 severance, termination or similar payments to the officers listed in Schedule 2.13 to the Disclosure Letter, except for those indicated in Schedule 2.13 to the Disclosure Letter. |

| 21. | Restrictive Documents |

Neither the Company nor its Subsidiary is subject to, or a party to, any restriction under its Articles, any Law, any claim, any Contract or instrument, any Encumbrance or any other restriction of any kind or character which E-10

would prevent or restrict (i) the consummation of the Contemplated Transactions, (ii) the compliance by the Company and its Subsidiary with the terms, conditions and provisions hereof, (iii) the declaration of dividends by the Company or its Subsidiary, (iv) any business practice of the Company and its Subsidiary, or (v) continuing the Discontinuance after the date hereof.

| 22. | Related Party Transactions |

Except as disclosed in the Company Public Documents:

| (a) | the Company has not (i) made any payment or loan to, or borrowed any moneys from or otherwise been                                                                     
 indebted to, any Related Party of the Company; or (ii) been a party to any Contract with any Related Party of the Company, in each case, excluding the Subsidiary; and |

| (b) | to the knowledge of the Company, no management or key employee, executive officer or director of the Company 
 and no entity which is an affiliate or associate of one or more of such individuals:                         |

| (i) | owns, directly or indirectly, any interest in (except for shares representing less than 10% of the outstanding                                                                                                                                        
 shares of any class or series of any publicly traded company), or is an officer, director or employee of or consultant to, any person which is, or is engaged in business as, a competitor of the Company or a lessor